Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test

RegulatoryapprovedAdvanceAD-Tx™Positive

AI Analysis

Summary

Castle Biosciences announced approval of its AdvanceAD-Tx™ diagnostic test by the New York State Department of Health, expanding access to the precision medicine test for guiding systemic treatment decisions in patients with moderate-to-severe atopic dermatitis.

Outcome Details

New York State Department of Health approval of AdvanceAD-Tx™ test

Importance:6/10

Sentiment:

0.70

diagnostic testprecision medicineregulatory approvalatopic dermatitisstate approval

Related Companies

$CSTL

Read the original article

Published by PR Newswire Biotech on July 14, 2026 8:30 PM

Read Original